Sidley Represents Gamma Biosciences on the Divestiture of Univercells Technologies

Sidley represented Gamma Biosciences, a life sciences platform created by global investment firm KKR to address the advanced therapy bioprocessing market, in the divestiture of its operating company, Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, to Donaldson Company, Inc (NYSE: DCI).

The Sidley team was led by David Zampa and Adam Runcorn (M&A and Private Equity), and included Zoe Woodhouse, Andrew N. Cebula, Jessica Edwards, Stanley Amoah, and Masie Awala (M&A and Private Equity); William Gwyn and Esther Crang (Global Finance); Sven De Knop, Jen Fernandez, and Alessandra Moroni (Global Arbitration, Trade and Advocacy); Patrick J. Harrison, Edward W. Sharon, and Bethany Wise (Antitrust/Competition); Maria Isabel Manley and Zina Chatzidimitriadou (Food, Drug and Medical Device); Jason Menzies, Suresh T. Advani, Wondha Cadet, and Fraser Tudor (Tax); Jade Williams-Adedeji and Michael Condlyffe (Real Estate); Peter McCorkell and Maeve Gillespie (Labor, Employment and Immigration); Francesca Blythe and Eleanor Dodding (Privacy and Cybersecurity); and Samantha Cumming (Commercial Litigation and Disputes).